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of revascularization were the only predictors of the extent of plaque
burden, whereas the established cardiovascular risk factor low-
density lipoprotein cholesterol (LDL-C) showed no statistically
significant relation to the amount of plaque burden (1).
Our group serially assessed left main stems of patients with
coronary artery disease treated by usual care with IVUS. Similar to the
findings of Nicholls et al. (1), at baseline (single-point observation) we
also found that patients with low versus high LDL-C levels had no
difference in coronary plaque burden (2). However, our patients with
high LDL-C levels showed significantly more plaque progression
during IVUS follow-up (serial observation) (2). Using these data, we
were able to show for the first time a significant linear relation
between LDL-C levels and coronary plaque progression as directly
measured by IVUS (2); later, this was confirmed by large pharmaco-
logical intervention trials with serial IVUS (3).
The aforementioned pieces of evidence suggest that the extent of
atherosclerotic plaque burden, as assessed at a single point in time,
does not sufficiently predict the rate of plaque progression during
follow-up. The extent of plaque burden can be in a balance between
plaque progression and regression. In other words, plaques may be
“progressors” despite a relatively small plaque burden, and plaques
may be “regressors” despite a relatively great plaque burden. This
underlies the fact that single-point observations are unable to charac-
terize the “dynamic status” of coronary lesions.
Coronary remodeling (changes in total vessel size) may be partly
responsible for the contradiction between the findings of single-point
versus serial assessment when analyzing percent plaque burden.
Plaque burden is in fact the relation between total vessel and plaque
size: if plaque size remains unchanged but vessel size decreases
(“negative remodeling”), the calculated percent plaque burden in-
creases; and if total vessel size increases (“positive remodeling”), plaque
burden decreases. Although the remodeling index shows a relatively
close relationship with the subsequent direction of true serial remod-
eling (4), we were unable to demonstrate a relation between plaque
burden and changes in total vessel dimensions (i.e., serial remodeling)
(5), which underlies the relative independence of actual coronary
remodeling from baseline plaque burden.
Finally, serial observational ultrasound data suggest that coro-
nary plaque progression by IVUS may be associated with increased
cardiovascular risk (6). We found that patients at the highest
estimated cardiovascular risk, as derived from 3 established cardio-
vascular risk scores, showed the highest plaque progression rates; in
addition, patients with greater plaque progression had significantly
more actual cardiovascular events during follow-up (6).
Thus, we believe that serial assessment of coronary plaques
(progression–regression)—if possible with volumetric analyses
(7)—should be the “gold standard” when analyzing the relation
between cardiovascular risk factors and coronary atherosclerosis.
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REPLY
We read with interest the letter by Drs. von Birgelen and
Hartmann with regard to our use of serial versus static assessments
of atheroma burden using intravascular ultrasound (IVUS) (1).
Although static assessments do not adequately evaluate the dy-
namic process of arterial wall remodeling, the ability to apply a
cross-sectional appraisal of a cohort of subjects provides a unique
opportunity to investigate factors that correlate with the extent of
atheroma throughout a coronary arterial segment. Serial assess-
ments of atheroma burden have assumed a pivotal role in the
elucidation of the factors, including pharmacological interventions,
that influence the natural history of atherosclerosis. It is for this
reason that the serial assessment of atheroma burden by IVUS has
become a surrogate end point in clinical trials (2–7).
The previous studies of the left main coronary artery cited by
these investigators (8) raise a number of important points with
regard to the study of atherosclerosis. A major limitation of these
studies includes their measurement of atheroma area at a single
cross-sectional slice of the left main coronary artery in a small
number of subjects (n  60), which were deemed to have the
smallest lumen area at baseline. As a result, these researchers used
the single image that corresponded to the most severe angiographic
stenosis in one specific segment of the coronary anatomy to make
speculative assessments of atherosclerosis. Given that atheroscle-
rosis is a systemic and not a focal process that would fit in a single
ultrasound frame, in addition to the well-established discord
between angiographic abnormalities and the extent of atheroma
within the arterial wall, it is uncertain what conclusions can be
made from investigating disease at one site.
The problem of using a single slice is further magnified in serial
studies. Serial assessment of atheroma burden requires precise
matching of that single slice, a task that is difficult to achieve in
many cases. In contrast, our report describes the relationship
between a broad range of clinical parameters and the volume of
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atheroma throughout a segment of coronary artery of at least 30
mm in length (1). This was performed in a large cohort of subjects
and includes sites that do not contain significant obstructive
disease. Although one segment was studied in each subject, each
epicardial coronary artery is reflected in the total cohort (i.e., this
is not a study of disease limited to the left main segment). Further,
the volumetric approach defines segments by the fixed anatomic
presence of arterial side branches and provides a greater opportu-
nity for precise matching and investigation of the factors that
influence the natural history of atherosclerosis.
Studying atherosclerosis within the left main coronary artery,
the investigators found no significant correlation between the level
of low density lipoprotein (LDL) cholesterol and atheroma burden
(8), in support of our findings. Interestingly, they found a signif-
icant correlation between baseline LDL cholesterol and progres-
sion of atheroma at the region studied. The degree of correlation
was much greater than what has been subsequently been reported
for the relationship between the degree of change in LDL
cholesterol and atheroma volume in patients treated with a statin
(6). Given that atherosclerosis is a complex pathological process
that results from the influence of a large number of factors on the
arterial wall and that there is a substantial overlap between levels of
LDL cholesterol and incidence of cardiovascular disease, it would
be surprising to expect anything greater than a mild correlation
between these factors at most.
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Most Asymptomatic Diabetic Patients Will
Not Benefit From Coronary Revascularization
In a study recently published in JACC, Scognamiglio et al. (1)
suggest that patients with type 2 diabetes mellitus with 1 other
risk factor should undergo routine stress imaging to diagnose
asymptomatic coronary artery disease (CAD), a strategy the
investigators believe will lead to early aggressive medical treatment
and more favorable coronary anatomy that is more suitable for
revascularization.
As cited by Scognamiglio et al. (1), the risk of major coronary
events in diabetic patients is similar to that of nondiabetic patients
with established coronary disease. Risk factors in these patients should
be treated as aggressively as in CAD patients even without evidence of
CAD on diagnostic imaging. Therefore, routine assessment of
asymptomatic diabetic patients by stress imaging to clarify the need
for more aggressive risk-factor modification is not warranted.
Both coronary revascularization by surgery (coronary artery
bypass graft [CABG]) and percutaneous coronary intervention
(PCI) differ in their influence on prognosis. Although no random-
ized study to date has shown PCI to improve elective patient
prognosis, CABG improves survival of elective patients in 4
categories: patients with left main coronary disease; patients with
3-vessel disease and decreased left ventricular function; patients
with multivessel disease involving the proximal left anterior de-
scending artery; and patients with diabetes mellitus and multivessel
disease (2). Most other patients undergo revascularization for
control of symptoms. For asymptomatic patients to benefit prog-
nostically from revascularization, one of the 4 previously men-
tioned indications must apply (and the procedure should be
CABG), otherwise no mortality benefit should be anticipated.
Revascularization, therefore, should be limited to patients who are
symptomatic or fall under 1 of the 4 previously mentioned
categories. Noninvasive testing should be performed in asymptom-
atic diabetics only if clinical assessment suggests that they belong
to a high-risk group. Only those patients with impaired cardiac
function or high-risk stress imaging should undergo coronary
angiography.
Early detection and aggressive modification of non–insulin-
dependent diabetes mellitus and other risk factors in adherence to
published guidelines (3,4) will help prevent CAD and its compli-
cations, whereas routine stress imaging and revascularization for
the most part will not.
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